10x Genomics Stock Analysis
| TXG Stock | USD 15.30 0.99 6.92% |
10X Genomics is undervalued with Real Value of 25.95 and Target Price of 60.33. The main objective of 10X Genomics stock analysis is to determine its intrinsic value, which is an estimate of what 10X Genomics is worth, separate from its market price. There are two main types of 10X Genomics' stock analysis: fundamental analysis and technical analysis.
The 10X Genomics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and 10X Genomics' ongoing operational relationships across important fundamental and technical indicators.
10X |
10X Stock Analysis Notes
About 94.0% of the company shares are owned by institutional investors. The book value of 10X Genomics was at this time reported as 5.97. The company has Price/Earnings To Growth (PEG) ratio of 0.13. 10X Genomics recorded a loss per share of 1.52. The entity had not issued any dividends in recent years. The firm had 1:2 split on the 17th of July 2006. 10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10X Genomics operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To find out more about 10X Genomics contact Serge Saxonov at 925 401 7300 or learn more at https://www.10xgenomics.com.10X Genomics Quarterly Total Revenue |
|
10X Genomics Investment Alerts
| 10X Genomics generated a negative expected return over the last 90 days | |
| 10X Genomics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 618.73 M. Reported Net Loss for the year was (255.1 M) with profit before taxes, overhead, and interest of 396.02 M. | |
| 10X Genomics has about 499.73 M in cash with (15.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39. | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: 10x Genomics Inc Shares Up 4.21 percent on Nov 22 |
10X Genomics Upcoming and Recent Events
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
10X Largest EPS Surprises
Earnings surprises can significantly impact 10X Genomics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-29 | 2024-09-30 | -0.34 | -0.3 | 0.04 | 11 | ||
2020-02-18 | 2019-12-31 | -0.11 | -0.07 | 0.04 | 36 | ||
2024-02-15 | 2023-12-31 | -0.36 | -0.41 | -0.05 | 13 |
10X Genomics Environmental, Social, and Governance (ESG) Scores
10X Genomics' ESG score is a quantitative measure that evaluates 10X Genomics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of 10X Genomics' operations that may have significant financial implications and affect 10X Genomics' stock price as well as guide investors towards more socially responsible investments.
10X Genomics Thematic Classifications
In addition to having 10X Genomics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Measuring and Control EquipmentUSA Equities from Measuring and Control Equipment industry as classified by Fama & French |
10X Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Venrock Management Vi Llc | 2024-09-30 | 2.1 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 1.9 M | Geode Capital Management, Llc | 2024-09-30 | 1.8 M | State Street Corp | 2024-06-30 | 1.6 M | Deerfield Management Co | 2024-09-30 | 1.5 M | Voloridge Investment Management, Llc | 2024-09-30 | 1.4 M | Millennium Management Llc | 2024-06-30 | 1.4 M | Point72 Asset Management, L.p. | 2024-09-30 | 1.2 M | Norges Bank | 2024-06-30 | 991.1 K | Fmr Inc | 2024-09-30 | 13.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 11.5 M |
10X Market Capitalization
The company currently falls under 'Mid-Cap' category with a total capitalization of 1.73 B.10X Profitablity
The company has Net Profit Margin of (0.29) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.27) %, which entails that for every $100 of revenue, it lost $0.27.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.32) | (0.33) | |
| Return On Assets | (0.26) | (0.28) | |
| Return On Equity | (0.34) | (0.33) |
Management Efficiency
10X Genomics has Return on Asset of (0.1137) % which means that on every $100 spent on assets, it lost $0.1137. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2487) %, meaning that it generated no profit with money invested by stockholders. 10X Genomics' management efficiency ratios could be used to measure how well 10X Genomics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.28. The current Return On Capital Employed is estimated to decrease to -0.33. At this time, 10X Genomics' Intangibles To Total Assets are most likely to slightly decrease in the upcoming years. The 10X Genomics' current Debt To Assets is estimated to increase to 0.12, while Non Current Assets Total are projected to decrease to roughly 210.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.32 | 6.64 | |
| Tangible Book Value Per Share | 6.14 | 6.45 | |
| Enterprise Value Over EBITDA | (30.68) | (32.21) | |
| Price Book Value Ratio | 8.85 | 5.94 | |
| Enterprise Value Multiple | (30.68) | (32.21) | |
| Price Fair Value | 8.85 | 5.94 | |
| Enterprise Value | 6.3 B | 5 B |
The management strategies employed by 10X Genomics' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Operating Margin (0.27) | Profit Margin (0.29) | Beta 1.873 | Return On Assets (0.11) | Return On Equity (0.25) |
Technical Drivers
As of the 25th of November, 10X Genomics shows the variance of 19.94, and Mean Deviation of 2.97. Compared to fundamental indicators, the technical analysis model gives you tools to check timely technical drivers of 10X Genomics, as well as the relationship between them. Please confirm 10X Genomics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if 10X Genomics is priced more or less accurately, providing market reflects its regular price of 15.3 per share. Given that 10X Genomics has information ratio of (0.15), we suggest you to validate 10X Genomics's prevailing market performance to make sure the company can sustain itself sooner or later.10X Genomics Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. 10X Genomics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for 10X Genomics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
10X Genomics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 10X Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on 10X Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 10X Genomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
10X Genomics Outstanding Bonds
10X Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. 10X Genomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most 10X bonds can be classified according to their maturity, which is the date when 10X Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US88023UAJ07 Corp BondUS88023UAJ07 | View | |
| US88023UAH41 Corp BondUS88023UAH41 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
10X Genomics Predictive Daily Indicators
10X Genomics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of 10X Genomics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
10X Genomics Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 5th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 9th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 4th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 4th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 26th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10X Genomics Forecast Models
10X Genomics' time-series forecasting models are one of many 10X Genomics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary 10X Genomics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About 10X Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how 10X Genomics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling 10X shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as 10X Genomics. By using and applying 10X Stock analysis, traders can create a robust methodology for identifying 10X entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.40) | (0.42) | |
| Operating Profit Margin | (0.43) | (0.45) | |
| Net Loss | (0.41) | (0.43) | |
| Gross Profit Margin | 0.66 | 0.86 |
Current 10X Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. 10X analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. 10X analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 60.33 | Buy | 17 | Odds |
Most 10X analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand 10X stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of 10X Genomics, talking to its executives and customers, or listening to 10X conference calls.
10X Stock Analysis Indicators
10X Genomics stock analysis indicators help investors evaluate how 10X Genomics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading 10X Genomics shares will generate the highest return on investment. By understating and applying 10X Genomics stock analysis, traders can identify 10X Genomics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 227.4 M | |
| Total Stockholder Equity | 741 M | |
| Capital Lease Obligations | 95.4 M | |
| Property Plant And Equipment Net | 344.9 M | |
| Cash And Short Term Investments | 388.7 M | |
| Net Invested Capital | 741 M | |
| Cash | 359.3 M | |
| 50 Day M A | 17.5668 | |
| Net Interest Income | 16.9 M | |
| Total Current Liabilities | 127.2 M | |
| Forward Price Earnings | 196.0784 | |
| Investments | 87.2 M | |
| Interest Expense | 33 K | |
| Stock Based Compensation | 166.9 M | |
| Common Stock Shares Outstanding | 117.2 M | |
| Tax Provision | 6.3 M | |
| Free Cash Flow | -64.7 M | |
| Other Current Assets | 18.8 M | |
| Accounts Payable | 15.7 M | |
| Net Debt | -263.9 M | |
| Other Operating Expenses | 884.4 M | |
| Non Current Assets Total | 369.1 M | |
| Liabilities And Stockholders Equity | 965.1 M | |
| Non Currrent Assets Other | 3.1 M |
Complementary Tools for 10X Stock analysis
When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |